Purpose One of the significant dose-limiting toxicities of irinotecan hydrochloride (CPT-11) is
severe diarrhea due to impairment of the intestinal membrane induced by the excreted CPT …

Abstract Irinotecan (CPT-11) treatments induce severe diarrhoea at a rate of> 40%. In
clinical trials, we evaluated the preventing effects of oral alkalization, which has been …

Purpose: An antitumor camptothecin derivative CPT-11 has proven a broad spectrum of
solid tumor malignancy, but its severe diarrhea has often limited its more widespread use …

Introduction: The main clinical adverse effect of irinotecan (CPT-11) therapy is diarrhoea.
Using a rat model, we attempted to study the effects of activated charcoal on the prevention …

Background: Diarrhea is a severe side effect of irinotecan, a pro-drug of SN-38 used for the
treatment of many types of cancers. Pre-clinical and clinical studies showed that decreasing …

Purpose. To investigate the excretion of irinotecan hydrochloride (CPT-11) and its active
metabolite, SN-38, into the gastrointestinal lumen via the biliary and/or intestinal membrane …

Purpose: Clinically, diarrhea is the major dose-limiting toxicity of irinotecan hydrochloride
(CPT-11). Using a rat model, we attempted to decrease the incidence of delayed-onset …

Diarrhoea is the major dose-limiting toxicity of irinotecan hydrochloride (CPT-11) in the
clinical setting. This study was designed to evaluate the effects of different pharmacological …

Abstract Purpose Irinotecan hydrochloride (CPT-11) is a potent topoisomerase I inhibitor
and is established and used widely as an antitumor agent. However, it sometimes causes …

One of the dose-limiting toxicities of irinotecan (CPT-11) is delayed-onset diarrhea, which is
the greatest barrier to treatment with CPT-11-containing regimens. CPT-11 is converted to its …